CD274 and neoplasm: It is well established that tumors with features such as low PD-L1 expression, TMB, and TIS expression do not respond as well to checkpoint inhibitors.15 16 28 29 The predictive value of these biomarkers for targeted therapy is less definitive, although higher levels of tumor immune markers were associated with greater treatment benefit in the phase 3 COMBI-AD (dabrafenib plus trametinib) trial.30 In our analyses, higher levels of intratumoral T cells (assessed via TIS or IHC) were positively prognostic regardless of treatment arm.